CGEN

Compugen Ltd. (NASDAQ:CGEN) is an Israeli clinical-stage biotechnology company founded in 1993 and headquartered in Holon, Israel. The company went public in 2000 and has evolved from its origins in computational biology to become a focused immuno-oncology drug developer. Compugen utilizes its proprietary computational discovery platform to identify novel immune checkpoint targets and develops therapeutic antibodies to treat cancer patients. The company has established strategic partnerships with major pharmaceutical companies including AstraZeneca, Bayer, and Gilead Sciences to advance its pipeline of innovative cancer treatments.